Tissue Regenix Group (FRA:LSW) ROCE %: -2.35% (As of Jun. 2025)


FRA:LSW Tissue Regenix Group PLC FRA:LSW
10 GF Score
Price €0.07
GF Value €0.84
! 5 Warning Signs
View Full Analysis

What is Tissue Regenix Group ROCE %?

Tissue Regenix Group FRA:LSW 10 ROCE % is -2.35% as of Jun. 2025. GuruFocus rates FRA:LSW with a GF Score™ of 10/100 and a GF Value™ of €0.84. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tissue Regenix Group's annualized ROCE % for the quarter that ended in Jun. 2025 was -2.35%.

Tissue Regenix Group  (FRA:LSW) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tissue Regenix Group ROCE % Related Terms

Tissue Regenix Group ROCE % Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group ROCE % Chart

Tissue Regenix Group Annual Data
Trend Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.52 -10.53 -5.31 -2.53 0.84

Tissue Regenix Group Semi-Annual Data
Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.09 -4.00 1.71 -0.07 -2.35
FRA:LSW
10GF Score
Tissue Regenix Group PLC FRA:LSW
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tissue Regenix Group ROCE % Calculation

Tissue Regenix Group's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=0.304/( ( (39.654 - 4.342) + (43.305 - 5.878) )/ 2 )
=0.304/( (35.312+37.427)/ 2 )
=0.304/36.3695
=0.84 %

Tissue Regenix Group's ROCE % of for the quarter that ended in Jun. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2025 )  (Q: Dec. 2024 )(Q: Jun. 2025 )
=-0.84/( ( (43.305 - 5.878) + (40.912 - 6.861) )/ 2 )
=-0.84/( ( 37.427 + 34.051 )/ 2 )
=-0.84/35.739
=-2.35 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -2.35% mean?
Tissue Regenix Group (FRA:LSW) has a ROCE % of -2.35% as of Jun. 2025.
Is Tissue Regenix Group's ROCE % too high?
Tissue Regenix Group's current ROCE % is -2.35%. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's ROCE % compare to VRTX and REGN?
Tissue Regenix Group's ROCE % of -2.35% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Tissue Regenix Group's current ROCE % is -2.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current ROCE % of -2.35%. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current ROCE % is -2.35%. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current ROCE % is -2.35% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?

Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued. The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.

Key valuation signals for FRA:LSW:

  • ROCE %: -2.35%
  • GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
  • GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score

Get the complete analysis for FRA:LSW

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.84
GF Value